![Brian Burkavage](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Brian Burkavage
Financieel Directeur/CFO bij
DAMORA THERAPEUTICS, INC.
Vermogen: 35 $ op 31-05-2026
Profiel
Brian Burkavage is Chief Financial & Accounting Officer at Damora Therapeutics, Inc. starting in 2026.
Former positions include Chief Accounting Officer at IO Biotech, Inc. from 2022 to 2025, Controller at Passage Bio, Inc. from 2020 to 2021, and Director-Financial Planning & Analysis at Aclaris Therapeutics, Inc. from 2017 to 2020.
Education includes undergraduate and graduate degrees from the University of Notre Dame.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
IO BIOTECH, INC. 0,02% | 02-04-2025 | 11.500 ( 0,02% ) | 35 $ | 31-05-2026 |
Actieve functies van Brian Burkavage
| Bedrijven | Functie | Begin |
|---|---|---|
| DAMORA THERAPEUTICS, INC. | Financieel Directeur/CFO | 01-05-2026 |
Eerdere bekende functies van Brian Burkavage
| Bedrijven | Functie | Einde |
|---|---|---|
| IO BIOTECH, INC. | Comptroller/Controller/Auditor | 12-12-2025 |
| PASSAGE BIO, INC. | Comptroller/Controller/Auditor | 01-01-2021 |
| ACLARIS THERAPEUTICS, INC. | Corporate Officer/Principal | 01-01-2020 |
Opleiding van Brian Burkavage
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
20
Eerstegraads connecties
5
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
University of Notre Dame
 University of Notre Dame Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aclaris Therapeutics, Inc.
 Aclaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel drug candidates for immuno-inflammatory diseases | Health Technology |
Passage Bio, Inc.
 Passage Bio, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of monogenic central nervous system disorders | Health Technology |
Galecto, Inc.
 Galecto, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of severe diseases | Health Technology |
IO Biotech, Inc.
 IO Biotech, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel, immune-modulating cancer therapies | Health Technology |
